Unmasking data in the COVID-19 vaccine era – New podcast episode

Signal detection / 30 January 2023

What are the implications for signal detection when new approaches to reporting create greater data streams than have ever been present for older medicinal products?


The successful rollout of the COVID-19 vaccines was supported by a stream of reports of potential adverse drug reactions. This is great for vaccine safety, but what of the ability to detect signals from other drugs?

In the latest episode of Drug Safety Matters, join Federica Santoro and Sara Vidlin, a data scientist at UMC, as they discuss how this imbalance of COVID-19 vaccine reports presents challenges for detecting signals for other drugs through the statistical phenomenon of ‘masking’. Learn how they detect it, how it affects their data analysis, and what researchers can do to ‘unmask’ impacted data to ensure accurate drug reaction surveillance.

This episode is part of the Uppsala Reports long read series, a selection of the most relevant stories from Uppsala Reports magazine in audio format. Read the original article here. Subscribe by visiting the Drug Safety Matters website.

You may also like


Vaccine surveillance systems explained – new podcast episode

Ever wondered how safety surveillance differs between vaccines and drugs? Find out in the latest episode of the Drug Safety Matters podcast.

Signal detection / 25 August 2022

How VigiFlow is helping to keep the wheel of pharmacovigilance turning in South Africa

South Africa’s pharmacovigilance system has been evolving for over a decade with UMC’s data management system supporting them every step of the way.

Signal detection / 02 September 2024

Safety monitoring of orphan drugs: The SFDA experience

The safety of orphan drugs is hard to monitor as they target rare diseases afflicting small patient populations. However, an initiative led by the SFDA aims to improve this.

Signal detection / 12 August 2024